In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis

Journal of Immunology

Volumn 184, Issue 6, 2010, Pages 2769-2775

  Guimond, Martin ^a,d   Freud, Aharon G ^a   Mao, Hsiaoyin C ^a   Yu, Jianhua ^a   Blaser, Bradley W ^a   Leong, Jeffrey W ^c   Vandeusen, Jeffrey B ^a   Dorrance, Adrienne ^a   Zhang, Jianying ^a   Mackall, Crystal L ^c   Caligiuri, Michael A ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; GLYCOPROTEIN P 15095; INTERLEUKIN 15 RECEPTOR; FLT3 LIGAND PROTEIN; INTERLEUKIN 15; LIGAND; MEMBRANE PROTEIN; RECOMBINANT PROTEIN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ARTICLE; BLOOD CELL; BONE MARROW; BONE MARROW CELL; C57BL 6 MOUSE; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CHIMERA; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HOMEOSTASIS; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; TRANSGENIC MOUSE; TRANSPLANTATION;

ANIMALS; ANTIGENS, CD11C; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DENDRITIC CELLS; FEMALE; HOMEOSTASIS; HUMANS; INTERLEUKIN-15; KILLER CELLS, NATURAL; LIGANDS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RECOMBINANT PROTEINS;

EID: 77951924326     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900685     Document Type: Article

References (42)

1. + hematopoietic progenitor cells. Blood 87: 2632-2640.
2. + T cells. J. Exp. Med. 193: 219-231.
3. Kennedy, M. K., M. Glaccum, S. N. Brown, E. A. Butz, J. L. Viney, M. Embers, N. Matsuki, K. Charrier, L. Sedger, C. R. Willis, et al. 2000. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191: 771-780.
4. Lodolce, J. P., D. L. Boone, S. Chai, R. E. Swain, T. Dassopoulos, S. Trettin, and A. Ma. 1998. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9: 669-676.
5. Cooper, M. A., J. E. Bush, T. A. Fehniger, J. B. VanDeusen, R. E. Waite, Y. Liu, H. L. Aguila, and M. A. Caligiuri. 2002. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100: 3633-3638.
6. Dubois, S., J. Mariner, T. A. Waldmann, and Y. Tagaya. 2002. IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity 17: 537-547. (Pubitemid 35351500)
7. + T cell homeostasis. J. Exp. Med. 200: 825-834.
8. Sandau, M. M., K. S. Schluns, L. Lefrancois, and S. C. Jameson. 2004. Cutting edge: transpresentation of IL-15 by bone marrow-derived cells necessitates expression of IL-15 and IL-15Rα by the same cells. J. Immunol. 173: 6537-6541.
9. Mortier, E., T. Woo, R. Advincula, S. Gozalo, and A. Ma. 2008. IL-15Rα chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J. Exp. Med. 205: 1213-1225.
10. McKenna, H. J., K. L. Stocking, R. E. Miller, K. Brasel, T. De Smedt, E. Maraskovsky, C. R. Maliszewski, D. H. Lynch, J. Smith, B. Pulendran, et al. 2000. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95: 3489-3497.
11. + human natural killer cell progenitor that responds to interleukin-15. Blood 92: 3647-3657.
12. Péron, J. M., C. Esche, V. M. Subbotin, C. Maliszewski, M. T. Lotze, and M. R. Shurin. 1998. FLT3-ligand administration inhibits liver metastases: role of NK cells. J. Immunol. 161: 6164-6170.
13. + T cells by exogenous cell-associated antigens. Immunity 17: 211-220.
14. Blaser, B. W., S. Roychowdhury, D. J. Kim, N. R. Schwind, D. Bhatt, W. Yuan, D. F. Kusewitt, A. K. Ferketich, M. A. Caligiuri, and M. Guimond. 2005. Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. Blood 105: 894-901. (Pubitemid 40070781)
15. Fehniger, T. A., M. H. Shah, M. J. Turner, J. B. VanDeusen, S. P. Whitman, M. A. Cooper, K. Suzuki, M. Wechser, F. Goodsaid, and M. A. Caligiuri. 1999. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J. Immunol. 162: 4511-4520.
16. Ranson, T., C. A. Vosshenrich, E. Corcuff, O. Richard, W. Müller, and J. P. Di Santo. 2003. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood 101: 4887-4893. (Pubitemid 36857750)
17. Lucas, M., W. Schachterle, K. Oberle, P. Aichele, and A. Diefenbach. 2007. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26: 503-517. (Pubitemid 46602996)
18. Brasel, K., H. J. McKenna, P. J. Morrissey, K. Charrier, A. E. Morris, C. C. Lee, D. E. Williams, and S. D. Lyman. 1996. Hematologic effects of flt3 ligand in vivo in mice. Blood 88: 2004-2012. (Pubitemid 26307902)
19. Maraskovsky, E., K. Brasel, M. Teepe, E. R. Roux, S. D. Lyman, K. Shortman, and H. J. McKenna. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184: 1953-1962.
20. Lyman, S. D., L. James, T. Vanden Bos, P. de Vries, K. Brasel, B. Gliniak, L. T. Hollingsworth, K. S. Picha, H. J. McKenna, R. R. Splett, et al. 1993. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 75: 1157-1167.
21. Prlic, M., B. R. Blazar, M. A. Farrar, and S. C. Jameson. 2003. In vivo survival and homeostatic proliferation of natural killer cells. J. Exp. Med. 197: 967-976.
22. Schluns, K. S., E. C. Nowak, A. Cabrera-Hernandez, L. Puddington, L. Lefrançois, and H. L. Aguila. 2004. Distinct cell types control lymphoid subset development by means of IL-15 and IL-15 receptor a expression. Proc. Natl. Acad. Sci. USA 101: 5616-5621.
23. Brilot, F., T. Strowig, S. M. Roberts, F. Arrey, and C. Münz. 2007. NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Ra. J. Clin. Invest. 117: 3316-3329.
24. Iizuka, K., D. D. Chaplin, Y. Wang, Q. Wu, L. E. Pegg, W. M. Yokoyama, and Y. X. Fu. 1999. Requirement for membrane lymphotoxin in natural killer cell development. Proc. Natl. Acad. Sci. USA 96: 6336-6340.
25. Lian, R. H., R. K. Chin, H. E. Nemeth, S. L. Libby, Y. X. Fu, and V. Kumar. 2004. A role for lymphotoxin in the acquisition of Ly49 receptors during NK cell development. Eur. J. Immunol. 34: 2699-2707.
26. Ware, C. F., P. D. Crowe, M. H. Grayson, M. J. Androlewicz, and J. L. Browning. 1992. Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J. Immunol. 149: 3881-3888.
27. Blauvelt, A., H. Asada, V. Klaus-Kovtun, D. J. Altman, D. R. Lucey, and S. I. Katz. 1996. Interleukin-15 mRNA is expressed by human keratinocytes, Langerhans cells, and blood-derived dendritic cells and is downregulated by ultraviolet B radiation. J. Invest. Dermatol. 106: 1047-1052.
28. Rückert, R., K. Brandt, E. Bulanova, F. Mirghomizadeh, R. Paus, and S. Bulfone-Paus. 2003. Dendritic cell-derived IL-15 controls the induction of CD8 T cell immune responses. Eur. J. Immunol. 33: 3493-3503.
29. de Saint-Vis, B., I. Fugier-Vivier, C. Massacrier, C. Gaillard, B. Vanbervliet, S. Aït-Yahia, J. Banchereau, Y. J. Liu, S. Lebecque, and C. Caux. 1998. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J. Immunol. 160: 1666-1676.
30. Jonuleit, H., K. Wiedemann, G. Müller, J. Degwert, U. Hoppe, J. Knop, and A. H. Enk. 1997. Induction of IL-15 messenger RNA and protein in human blood-derived dendritic cells: a role for IL-15 in attraction of T cells. J. Immunol. 158: 2610-2615.
31. Koka, R., P. Burkett, M. Chien, S. Chai, D. L. Boone, and A. Ma. 2004. Cutting edge: murine dendritic cells require IL-15Rα to prime NK cells. J. Immunol. 173: 3594-3598.
32. Kobayashi, H., S. Dubois, N. Sato, H. Sabzevari, Y. Sakai, T. A. Waldmann, and Y. Tagaya. 2005. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 105: 721-727.
33. Ohteki, T., H. Tada, K. Ishida, T. Sato, C. Maki, T. Yamada, J. Hamuro, and S. Koyasu. 2006. Essential roles of DC-derived IL-15 as a mediator of inflammatory responses in vivo. J. Exp. Med. 203: 2329-2338.
34. Hochweller, K., J. Striegler, G. J. Hämmerling, and N. Garbi. 2008. A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. Eur. J. Immunol. 38: 2776-2783.
35. Damiani, D., R. Stocchi, P. Masolini, A. Michelutti, A. Geromin, A. Sperotto, C. Skert, M. Michieli, M. Baccarani, and R. Fanin. 2003. CD34+-selected versus unmanipulated autologous stem cell transplantation in multiple myeloma: impact on dendritic and immune recovery and on complications due to infection. Ann. Oncol. 14: 475-480.
36. Giraud, S., N. Dhedin, H. Gary-Gouy, P. Lebon, J. P. Vernant, and A. Dalloul. 2005. Plasmacytoid dendritic cell reconstitution following bone marrow transplantation: subnormal recovery and functional deficit of IFN-α/β production in response to herpes simplex virus. J. Interferon Cytokine Res. 25: 135-143. (Pubitemid 40354833)
37. Sakurai, T., N. Wakimoto, M. Yamada, S. Shimamura, and K. Motoyoshi. 1998. Effect of macrophage colony-stimulating factor on mouse NK 1.1+ cell activity in vivo. Int. J. Immunopharmacol. 8: 401-413.
38. Ranson, T., C. A. Vosshenrich, E. Corcuff, O. Richard, V. Laloux, A. Lehuen, and J. P. Di Santo. 2003. IL-15 availability conditions homeostasis of peripheral natural killer T cells. Proc. Natl. Acad. Sci. USA 100: 2663-2668.
39. Chen, Y. M., W. K. Yang, C. C. Ting, W. Y. Tsai, D. M. Yang, J. Whang-Peng, and R. P. Perng. 1997. Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients. Chest 112: 960-966.
40. Higano, C. S., N. J. Vogelzang, J. A. Sosman, A. Feng, D. Caron, and E. J. Small. 2004. Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer. Clin. Cancer Res. 10: 1219-1225.
41. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, et al. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100. (Pubitemid 34229476)
42. Daro, E., E. Butz, J. Smith, M. Teepe, C. R. Maliszewski, and H. J. McKenna. 2002. Comparison of the functional properties of murine dendritic cells generated in vivo with Flt3 ligand, GM-CSF and Flt3 ligand plus GM-SCF. Cytokine 17: 119-130. (Pubitemid 34920656)